The approval is based on results from an ongoing non-comparative clinical study (EPIC3) in which 1,336 patients with moderate to severe fibrosis or cirrhosis who failed previous treatment
The docosahexaenoic acid (DHA) patent was the subject of a challenge by Aventis Research Technologies and Nagase. The company believes that it is probable that at least one
Protonix delayed-release oral suspension can be administered orally in applesauce or apple juice, or through a nasogastric tube. Protonix delayed-release oral suspension is indicated for the treatment and
The addition of ViaCell’s product ViaCord and its highly qualified sales and marketing organization provides PerkinElmer with a leading offering in the rapidly growing cord blood banking business,
The open label, multi-center safety and efficacy trial is expected to begin enrolling patients by early 2008. The primary objective of the trial is to assess the overall
A new Office of Strategy and Growth will identify opportunities for future growth that are distinct from those being pursued by the company’s existing businesses. A Surgical Care
The FDA approval for maintenance treatment of schizophrenia was based on clinical trial results in which patients who had responded to Seroquel for the treatment of schizophrenia for
The bioequivalence study of ANX-530 was a crossover comparison of ANX-530 and Navelbine with a primary objective of demonstrating the pharmacokinetic equivalence of ANX-530 and Navelbine. Determining the
Panacea says CC Detect is a simple blood test that should facilitate the identification of individuals with cancer of the colon and rectum when used in conjunction with
BioMarin established a marketing and distribution agreement with AnGes in December 2006, through which AnGes obtained exclusive rights to market Naglazyme in the Japanese market. Naglazyme was already
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.